CHARLOTTESVILLE, VA – February 2, 2007 – Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary approach to treat life-threatening diseases, today announced that it has received a $0.5 million grant (N00014-07-C-0424) from the Office of Naval Research (ONR). The funds will be used to support the transition of the company’s lead [...]

Human Testing Expected to Begin in Early 2007 CHARLOTTESVILLE, VA — October 17, 2006 — Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary mechanism of action to treat life-threatening diseases, today announced that it has completed all animal toxicology studies required by the U.S. Food and Drug Administration (FDA) to file [...]

Charlottesville, VA — December 5, 2005 — Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary mechanism of action to treat life-threatening diseases, today announced that it has completed a $1.35 million private equity round. Proceeds will be used to transition trans sodium crocetinate (TSC), the company’s lead compound, to the clinical [...]

Charlottesville, VA — October 29, 2004 —Diffusion Pharmaceuticals LLC, a pharmaceutical company which discovers and develops novel small-molecule therapeutics for the treatment of oxygen deficiency in tissues, today announced its selection as the winner of the Virginia’s Technology Capital Access Forum’s (VTCAF) business plan competition, receiving the $10,000 cash prize sponsored by Third Security, LLC. [...]

CHARLOTTESVILLE, VA — Tuesday, September 7, 2004 — Diffusion Pharmaceuticals, an early-stage pharmaceutical company which discovers and develops novel small-molecule therapeutics, today announced it has been awarded a $1 million appropriation in the FY 2005 Defense Budget, which President Bush signed last month. These funds are allocated for studies to advance its lead compound, trans [...]